Consensus Merck & Co., Inc.

Equities

MRK

US58933Y1055

Real-time Estimate Cboe BZX Other stock markets 04:00:03 2024-04-19 pm EDT			5-day change	1st Jan Change
126.2 ^USD	+0.77%		+0.14%	+15.49%

02:55pm	Merck Says Health Canada Approved Keytruda Plus Fluoropyrimidine, Platinum-Containing-Chemotherapy for Gastric Cancer	MT
02:42pm	BMO Capital Adjusts Price Target on Merck & Company to $148 From $132	MT

Evolution of the average Target Price on Merck & Co., Inc.

Price target over the last 5 years

History of analyst recommendation changes

e8289451cc41cc29b90b556.VnOGIOS2iFxFtt6TQJBJFWBoL8-ohBAJJ5dUgjMb5WU.PRXhEovV6W8E2p37EPx-QQIaZofgxXtGcv83yEcvlhECR-MSrILBHxCOjw~92f8cb85f617cbbc832fef8890219d30

Analyst Recommendations on Merck & Co., Inc.

BMO Capital Adjusts Price Target on Merck & Company to $148 From $132	08:42am	MT
Leerink Partners Raises Merck's Price Target to $134 From $129	07:41am	MT
Zacks Adjusts Price Target on Merck & Company to $132 From $128	Apr. 15	MT
Berenberg Raises Price Target on Merck & Company to $143 From $140, Maintains Buy Rating	Apr. 08	MT
Truist Securities Raises Merck Price Target to $142 From $139, Maintains Buy Rating	Mar. 27	MT
Wells Fargo Raises Price Target on Merck to $135 From $130, Maintains Equal-Weight Rating	Mar. 27	MT
Societe Generale Downgrades Merck to Sell From Hold, Raises Price Target to $104 From $103	Mar. 11	MT
ANALYST RECOMMENDATIONS : Doordash, Merck, Eli Lilly, Walt Disney, Pearson...	Mar. 04
UBS Adjusts Merck & Co.'s Price Target to $148 From $135, Maintains Buy Rating	Feb. 02	MT
Wells Fargo Raises Merck's Price Target to $130 From $125, Maintains Equalweight Rating	Feb. 02	MT
Truist Securities Raises Merck's Price Target to $139 From $122, Maintains Buy Rating	Feb. 02	MT
Goldman Sachs Raises Merck's Price Target to $134 From $128, Maintains Buy Rating	Feb. 02	MT
Barclays Raises Merck's Price Target to $145 From $135, Keeps Overweight Rating	Feb. 02	MT
Jefferies Raises Merck's Price Target to $140 From $136, Keeps Buy Rating	Feb. 02	MT
Did you expect anything different?	Feb. 01
Futures climb following Wall St selloff after Fed holds rates steady	Feb. 01	RE
Deutsche Bank Adjusts Merck & Company Price Target to $135 From $115, Maintains Buy Rating	Jan. 29	MT
BofA Securities Raises Merck Price Target to $135 From $130, Maintains Buy Rating	Jan. 26	MT
Barclays Raises Merck's Price Target to $135 From $130, Maintains Overweight Rating	Jan. 23	MT
UBS Adjusts Merck & Company Price Target to $135 From $122, Maintains Buy Rating	Jan. 17	MT
TD Cowen Upgrades Merck to Outperform From Market Perform, Raises Price Target to $135 From $125	Jan. 04	MT
Euphoria subsides for Triple-Witching Day	Dec. 15
Wall St set for higher open after Fed hints at rate cuts	Dec. 14	RE
Goldman Sachs Adjusts Merck & Co.'s Price Target to $128 From $131, Keeps Buy Rating	Dec. 12	MT
Morgan Stanley Cuts Price Target on Merck to $116 From $118, Keeps Equalweight Rating	Dec. 12	MT

More recommendations

Analysts' Consensus

Sell

Buy

Mean consensus

BUY

Number of Analysts

Last Close Price

125.2 USD

Average target price

137.7 USD

Spread / Average Target

+9.92%

High Price Target

148 USD

Spread / Highest target

+18.18%

Low Price Target

114 USD

Spread / Lowest Target

-8.97%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Merck & Co., Inc.

Zacks Investment Research
Berenberg Bank
Truist Securities
Wells Fargo Securities
Societe Generale
UBS
Goldman Sachs
Barclays
Jefferies & Co.
Deutsche Bank Securities
BofA Securities
TD Cowen
Morgan Stanley
BMO Capital
HSBC
Atlantic Equities
Citigroup
Guggenheim
Credit Suisse
JPMorgan Chase
Wolfe Research
SVB Securities LLC
Cantor Fitzgerald
Daiwa Securities
Cowen
SVB Leerink
Argus
RBC Capital Markets
RBC	Randall Stanicky
JPMORGAN

Ratings for Merck & Co., Inc.

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar